Developing microbiome-directed therapeutics for treating childhood undernutrition
Using multiomic methods, including SomaScan® proteomics, to judge clinical efficacy
Abstract
This 1-hour talk covers how researchers are testing the hypothesis that perturbations in the normal development of the gut microbiome are causally related to childhood undernutrition, a devastating global health problem whose long-term sequelae include metabolic and immune dysfunction, stunting, and neurodevelopmental abnormalities, which remains largely refractory to current therapeutic interventions.
Learning objectives
This 1-hour talk covers how researchers are testing the hypothesis that perturbations in the normal development of the gut microbiome are causally related to childhood undernutrition, a devastating global health problem whose long-term sequelae include metabolic and immune dysfunction, stunting, and neurodevelopmental abnormalities, which remains largely refractory to current therapeutic interventions.
- Understand evidence that impaired postnatal development of the gut microbiota is causally related to childhood undernutrition
- Understand how preclinical gnotobiotic animal models can be used to develop new microbiota-directed therapeutics
- Understand how multiomic methods, including SomaScan proteomics, can be used to judge the efficacy and mechanism of action of these therapeutics in clinical studies
Jeffrey Gordon, MD
Director, Edison Family Center for Genome Sciences and Systems Biology, Washington University
Michael J. Barratt, PhD
Executive Director, Center for Gut Microbiome and Nutrition Research, Washington University
Developing microbiome-directed therapeutics for treating childhood undernutrition
A webinar presented by Jeffrey Gordon, MD, and Michael J. Barratt, PhD
Request Information
More webinars
WebinarCorrelation of a Nonalcoholic Steatohepatitis Proteomic Test with Clinical Outcomes
In this webinar, Anne Minnich, PhD, biomarker consultant at Bristol Myers Squibb, presents research on the use of the new SomaSignal(TM) NASH bundle test in a recently completed clinical trial.
WebinarHarnessing AI and proteomics for glioblastoma
The development and advancement of aptamer technology opens vast possibilities for unlocking the biocomplexity available within proteomics. Learn more about the powerful tools that are enabling the discovery and validation of clinically relevant biomarkers and accelerating research.
WebinarMapping the human mucosal immune response to respiratory viruses
Conventionally, human immune responses have been extensively characterized using blood. Immune cells, though abundant in blood, are also found in various tissues in varying numbers and with locally relevant functional specification. Assessing immune responses in the airways over the course of infection and convalescence is critical to comprehensively mapping immunity to respiratory viral infections including influenza and SARS-CoV-2.